Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan + amoxicillin dual therapy for Hp-positive chronic gastritis
ChiCTR2500107181Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of keverprazan and amoxicillin in chronic gastritis and Helicobacter pylori infection (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Hp eradication rate 4 weeks after completion of eradication therapy. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
keverprazanamoxicillin
03
Conditions
chronic gastritisHelicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500107181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107181.